clinical trial

Fort Worth’s AyuVis Gets FDA Fast‑Track Designation for Its Drug for Babies with a Chronic Lung Disease

by | Aug 23, 2024
Premature babies diagnosed with bronchopulmonary dysplasia (BPD) face the risk of rehospitalization, delayed brain development, and respiratory problems throughout childhood. No FDA-approved therapies are available for BPD—which is why the new FDA designation for AyuVis's drug candidate, AVR-48, could lead to game-changing impact.
MORE
Fort Worth’s AyuVis Is One Step Closer to Protecting Pre-Term Babies from a Leading Cause of Death
by | Mar 31, 2022
Fort Worth-based AyuVis just received its second patent in three months for its immunotherapy treatments that protect pre-term babies from a debilitating chronic lung disease that affects many pre-term infants on ventilators.

The startup's lead drug candidate—AVR-48—is scheduled for clinical trials this summer.
MORE
eyevensys
Fort Worth Biotech Eyevensys Completes $30M Series B Funding Round
by | Jan 8, 2020
The startup plans to use the funding to continue developing its technology and to position it as an innovator in ophthalmology. Eyevensys’ tech is a gene therapy platform to deliver ocular drugs via an electrotransfection system to the ciliary muscle of the eye.
MORE
Protecting your privacy. We have strengthened our Privacy Policy to better protect you. This Policy includes our use of cookies to give you the best online experience and provide functionality essential to our services. By clicking ‘I Accept’ or by continuing to use our website, you are consenting to our Privacy Policy.